Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Sponsor: St. Jude Children's Research Hospital
Summary
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
Key Details
Gender
All
Age Range
Any - 21 Years
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2008-05-09
Completion Date
2026-05
Last Updated
2025-12-23
Healthy Volunteers
No
Conditions
Interventions
Peginterferon alfa-2b
Given either IV or SQ. Therapeutic drug class: interferon.
Temozolomide
Given PO. Therapeutic drug class: antineoplastic agent.
Recombinant interferon alfa-2b
Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
Locations (3)
Rady Children's Hospital
San Diego, California, United States
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
Houston, Texas, United States